INSTAND e.V.
Gesellschaft zur Förderung der Qualitätssicherung in medizinischen Laboratorien e. V.
40223 Düsseldorf Ubier - Str. 20 , 40093 Postfach 250211, Germany

# Certificate

## Virusimmunology June 2014

Deadline of EQAS : 27.6.2014

**Lenka Hanakova (participant 1570 E )**
**TestLine**
**Clinical Diagnostics s.r.o.**
**Krizikova 68**
**61200 Brno**
**Tschechien**

This is to certify that the above mentioned participant has s u c c e s s f u l l y taken part in EQAS June 2014 with the following analyses:

Epstein-Barr virus (352) - Testing for anti-EBNA 1-IgG (15) **
Epstein-Barr virus (352) - Testing for anti-EBNA-IgM (25) **
Epstein-Barr virus (352) - Testing for anti-EA-IgG (30) **
Epstein-Barr virus (352) - Testing for anti-EA-IgM (40) **
Epstein-Barr virus (352) - Testing for anti-VCA-IgG (50) **
Epstein-Barr virus (352) - Testing for anti-VCA-IgM (60) **
Epstein-Barr virus (352) - Clinical interpretation of the tested samples (199) **

TBE (358) - Testing for anti-TBE-IgG or anti-TBE total (10) **
TBE (358) - Testing for avidity of anti-TBE-IgG (11) **
TBE (358) - Testing for anti-TBE-IgM (20) **

* valid for 6 months ** valid for 12 months *** valid for 2 years
R-B2: RiliBÄK-parameter subject to B2 R-B3: RiliBÄK-parameter subject to B3

Prof. Dr. M. Spannagl
(Chairman of the reference institution)

Prof. Dr. H. Zeichhardt
(Expert)

Düsseldorf, 29.9.2014

**June 2014**

**Lenka Hanakova (participant 1570 E )**
**TestLine**
**Clinical Diagnostics s.r.o.**
**Krizikova 68**
**61200 Brno**
**Tschechien**

**Valid results:**

## Epstein-Barr virus (352)

| sample | test | result |
|---|---|---|
| 352017 | Testing for anti-EBNA total-IgG (10) | negative |
| 352018 | Testing for anti-EBNA total-IgG (10) | positive |
| 352017 | Testing for anti-EBNA 1-IgG (15) | negative |
| 352018 | Testing for anti-EBNA 1-IgG (15) | positive |
| 352017 | Testing for anti-EBNA 1+2 - IgG (20) | negative |
| 352018 | Testing for anti-EBNA 1+2 - IgG (20) | positive |
| 352017 | Testing for anti-EBNA-IgM (25) | negative |
| 352018 | Testing for anti-EBNA-IgM (25) | negative |
| 352017 | Testing for anti-EA-IgG (30) | negative |
| 352018 | Testing for anti-EA-IgG (30) | negative |
| 352017 | Testing for anti-EA-IgA (35) | negative |
| 352018 | Testing for anti-EA-IgA (35) | negative |
| 352017 | Testing for anti-EA-IgM (40) | negative |
| 352018 | Testing for anti-EA-IgM (40) | negative |
| 352017 | Testing for anti-VCA-IgG (50) | negative |
| 352018 | Testing for anti-VCA-IgG (50) | positive |
| 352017 | Testing for anti-VCA-IgA (55) | negative |
| 352018 | Testing for anti-VCA-IgA (55) | negative |
| 352017 | Testing for anti-VCA-IgM (60) | negative |
| 352018 | Testing for anti-VCA-IgM (60) | negative |
| 352017 | Testing for anti-EBV-IgG (70) | negative |
| 352018 | Testing for anti-EBV-IgG (70) | positive |
| 352017 | Testing for anti-EBV-IgA (75) | negative |
| 352018 | Testing for anti-EBV-IgA (75) | negative |
| 352017 | Testing for anti-EBV-IgM (80) | negative |
| 352018 | Testing for anti-EBV-IgM (80) | negative |
| 352017 | Strip immunoblot assay (Strip IA) for anti-EBV-IgG (83) | negative |
| 352018 | Strip immunoblot assay (Strip IA) for anti-EBV-IgG (83) | positive |
| 352017 | Strip immunoblot assay (Strip IA) for anti-EBV-IgA (85) | negative |
| 352018 | Strip immunoblot assay (Strip IA) for anti-EBV-IgA (85) | negative |
| 352017 | Strip immunoblot assay (Strip IA) for anti-EBV-IgM (87) | negative |
| 352018 | Strip immunoblot assay (Strip IA) for anti-EBV-IgM (87) | negative |
| 352017 | Testing for heterophilic antibodies (90) | negative |
| 352018 | Testing for heterophilic antibodies (90) | negative |

+ : certificate granted

**Valid results:** Epstein-Barr virus (352) **June 2014**

| sample test | result | titer | target value interval |
|---|---|---|---|
| 352017 Testing for avidity of anti-VCA (150) | no avidity,nd | | |
| 352018 Testing for avidity of anti-VCA (150) | high | | 40 - 100 % |
| 352017 Testing for avidity of anti-EBV (without diff. of Ag-spec.) (170) | no avidity,nd | | |
| 352018 Testing for avidity of anti-EBV (without diff. of Ag-spec.) (170) | high | | 40 - 100 % |
| 352017 Testing for avidity of anti-EBV (183) | no avidity,nd | | |
| 352018 Testing for avidity of anti-EBV (183) | high | | |
| 352017 Clinical interpretation of the tested samples (199) | negative | | |
| 352018 Clinical interpretation of the tested samples (199) | past inf. | | |

+ : certificate granted

**INSTAND EQAS**
**Virusimmunology**

## Individual results

**participant 1570**
**29. 9.2014**
**page 3**

**Your results:**

**June 2014**

| sample test - method / reagent | | evaluation of your results | your qual. result |
|---|---|---|---|
| **Testing for anti-EBNA 1-IgG (15)** | | | |
| 352017 TestLine EIA EBV EBNA-1 IgG | | correct | negative |
| 352018 TestLine EIA EBV EBNA-1 IgG | + | correct | positive |
| **Testing for anti-EBNA-IgM (25)** | | | |
| 352017 TestLine EIA EBV EBNA-1 IgM | | correct | negative |
| 352018 TestLine EIA EBV EBNA-1 IgM | + | correct | negative |
| **Testing for anti-EA-IgG (30)** | | | |
| 352017 TestLine EIA EBV EA-D IgG | | correct | negative |
| 352018 TestLine EIA EBV EA-D IgG | + | correct | negative |
| **Testing for anti-EA-IgM (40)** | | | |
| 352017 TestLine EIA EBV EA-D IgM | | correct | negative |
| 352018 TestLine EIA EBV EA-D IgM | + | correct | negative |
| **Testing for anti-VCA-IgG (50)** | | | |
| 352017 TestLine EIA EBV VCA IgG | | correct | negative |
| 352018 TestLine EIA EBV VCA IgG | + | correct | positive |
| **Testing for anti-VCA-IgA (55)** | | | |
| 352017 TestLine EIA EBV VCA IgA | | correct | negative |
| 352018 TestLine EIA EBV VCA IgA | | false | positive |
| **Testing for anti-VCA-IgM (60)** | | | |
| 352017 TestLine EIA EBV VCA IgM | | correct | negative |
| 352018 TestLine EIA EBV VCA IgM | + | correct | negative |
| **Clinical interpretation of the tested samples (199)** | | | |
| 352017 | | correct | negative |
| 352018 | + | correct | past Inf. |

+ : certificate granted

**INSTAND EQAS**
**Virusimmunology**

## Individual results

**participant 1570**
**29. 9.2014**
**page 4 -E**

**June 2014**

**Lenka Hanakova (participant 1570 E )**
**TestLine**
**Clinical Diagnostics s.r.o.**
**Krizikova 68**
**61200 Brno**
**Tschechien**

**Valid results:**

## TBE (358)

| sample test | result | titer | target value interval |
|---|---|---|---|
| 358017 Testing for anti-TBE-IgG or anti-TBE total (10) | positive | | |
| 358018 Testing for anti-TBE-IgG or anti-TBE total (10) | positive | | |
| 358017 Testing for avidity of anti-TBE-IgG (11) | high | | 40 - 100 % |
| 358018 Testing for avidity of anti-TBE-IgG (11) | high | | 40 - 100 % |
| 358017 Testing for anti-TBE-IgM (20) | negative | | |
| 358018 Testing for anti-TBE-IgM (20) | negative | | |

**Your results:**

| sample test - method / reagent | | evaluation of your results | your qual. result | your titer | your other result |
|---|---|---|---|---|---|
| **Testing for anti-TBE-IgG or anti-TBE total (10)** | | | | | |
| 358017 TestLine EIA TBE Virus IgG | | correct | positive | | |
| 358018 TestLine EIA TBE Virus IgG | + | correct | positive | | |
| **Testing for avidity of anti-TBE-IgG (11)** | | | | | |
| 358017 TestLine EIA TBE Virus IgG Avidität | | correct | high | | |
| 358017 TestLine EIA TBE Virus IgG Avidität | | correct | | | 41 % |
| 358018 TestLine EIA TBE Virus IgG Avidität | | correct | high | | |
| 358018 TestLine EIA TBE Virus IgG Avidität | + | correct | | | 60 % |
| **Testing for anti-TBE-IgM (20)** | | | | | |
| 358017 TestLine EIA TBE Virus IgM | | correct | negative | | |
| 358018 TestLine EIA TBE Virus IgM | + | correct | negative | | |

+ : certificate granted